Skip to main content
Home / The International Journal of Tuberculosis and Lung Disease, Volume 14, Number 4

Cost-effectiveness of QuantiFERON®-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection

Buy Article:

$34.78 + tax (Refund Policy)

OBJECTIVE: To evaluate the cost-effectiveness of the tuberculin skin test (TST), the QuantiFERON®-TB Gold test (QFT) and a combination of TST and QFT (TST+QFT) for diagnosing latent tuberculosis infection (LTBI) in France in a bacille Calmette-Guérin (BCG) vaccinated population.

METHODS: A decision analysis model evaluated three strategies among simulated adults in close contact with tuberculosis (TB). We calculated direct lifetime medical costs, life expectancies and incremental cost-effectiveness ratios (ICERs).

RESULTS: The discounted direct medical costs of care per patient of no testing, TST, QFT and TST+QFT were respectively €417, €476, €443 and €435, while discounted life expectancies were respectively 25.030, 25.071, 25.073 and 25.062 years. TST had higher costs and lower efficacy than QFT; TST+QFT was associated with an ICER of €560 per year of life gained (YLG) compared to no testing, and QFT was associated with an ICER of €730/YLG compared to TST+QFT. The only scenario where QFT was associated with an ICER of >€75 000/YLG was when the prevalence of LTBI around TB was low (<5%) and TST specificity high (>90%).

CONCLUSIONS: In France, for the diagnosis of LTBI after close contact with TB, the TST is more expensive and less effective than QFT. Although it is more expensive, QFT is more effective and cost-effective than TST+QFT under a wide range of realistic test performance scenarios.

Keywords: LTBI; QuantiFERON®-TB test; contact investigation; cost-effectiveness analysis; tuberculosis disease

Document Type: Regular Paper

Affiliations: 1: Institut National de la Santé et de la Recherche Médicale (INSERM) U795, Faculté de Médecine, Lille, France; INSERM EA2694, Faculté de Médecine, Lille, France 2: Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche en Santé 707, Paris, France 3: Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Tourcoing, France 4: Groupe d'Etude sur le Risque d'Exposition au Sang, Unité de Formation et de Recherche Médical, Hôpital Bichat, Paris, France; and Service d'Infectiologie, Hôpital Bichat-Claude Bernard, Paris, France

Publication date: 01 April 2010

More about this publication?

  • The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.

    The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites

Share Content

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content